The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity

Blood Cancer Journal

Volumn 4, Issue 7, 2014, Pages

  Ahmad, S M ^a   Svane, I M ^a   Andersen, M H ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 BLOCKING ANTIBODY; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PEPTIDE;

B CELL LYMPHOMA; CANCER CELL; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; IMMUNIZATION; IMMUNOLOGY; LEUKEMIA;

ANTIGENS, CD274; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNIZATION; LEUKEMIA; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84905375431     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.50     Document Type: Letter

References (15)

1. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
2. Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014; e-pub ahead of print 18 March 2014; doi:10.1038/leu.2014.108.
3. Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y et al. PD-1/PDL1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009; 23: 375-382.
4. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462-3473.
5. Atanackovic D, Luetkens T, Kroger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2013; 28: 993-1000.
6. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013; 27: 464-472.
7. Yang H, Bueso-Ramos C, Dinardo C, Estecio MR, Davanlou M, Geng QR et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2013; 28: 1280-1288.
8. Christiansson L, Soderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One 2013; 8: e55818.
9. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-3051.
10. Munir S, Andersen GH, Woetmann A, Odum N, Becker JC, Andersen MH. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 2013; 27: 2251-2253.
11. Munir S, Andersen GH, Met O, Donia M, Frosig TM, Larsen SK et al. HLA-restricted cytotoxic T cells that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Research 2013; 73: 1674-1776.
12. Ahmad SM, Larsen SK, Svane IM, Andersen MH. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 2014; 28: 236-238.
13. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471-476.
14. Goker E, Kheradpour A, Waltham M, Banerjee D, Tong WP, Elisseyeff Y et al. Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. Leukemia 1995; 9: 274-276.
15. Drexler HG, Dirks WG, Matsuo Y, MacLeod RA. False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia 2003; 17: 416-426.